Prevention of Premalignant Progression of Human Breast Cancer
Abstract
The main aim of these experiments is to test the effect of selected drugs on premalignant progression of a defined set of human breast premalignant cell lines using a newly developed intraductal xenograft model. In the first phase of these experiments, we used three cell lines, two of which show different background rates of progression to invasive ductal beast cancer (DCIS.com and CCH1.dcis) and a third line, SUM225, which does not exhibit local invasion. The basic protocol involves intraductal injection of cells into primary duct of immunocompromised hosts, followed by a 4-6 week treatment of agents beginning at 6 weeks after intraductal injection. The endpoints are extent of growth in vivo, Qt-PCR and IHC of biomarkers specific for the chemopreventive drug of interest. The initial experiments involve a 3 x 3 design (three cell lines and three agents). Six groups have been set up. The initial results indicate that the protocol is effective and will provide information on the chemopreventive efficacy of specific drugs. The initial data suggest the efficacy is a function of the molecular alterations in the premalignant cell line and the specific target of the chemopreventive agent.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 2011
- Accession Number
- ADA552885
Entities
People
- Daniel Medina
- Powel Brown
Organizations
- Baylor College of Medicine